This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Y.
Right arrow Articles by Wyatt, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y.
Right arrow Articles by Wyatt, R.

 Previous Article  |  Next Article 

Journal of Virology, February 2006, p. 1414-1426, Vol. 80, No. 3
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.3.1414-1426.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants{dagger}

Y. Li,1 K. Svehla,1 N. L. Mathy,2 G. Voss,2 J. R. Mascola,1 and R. Wyatt1*

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland,1 GlaxoSmithKline Biologicals, Rixensart, Belgium2

Received 1 August 2005/ Accepted 26 August 2005

We previously reported that soluble, stable YU2 gp140 trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein immunogens could elicit improved breadth of neutralization against HIV-1 isolates compared to monomeric YU2 gp120 proteins. In this guinea pig immunization study, we sought to extend these data and determine if adjuvant could quantitatively or qualitatively alter the neutralizing response elicited by trimeric or monomeric immunogens. Consistent with our earlier studies, the YU2 gp140 immunogens elicited higher-titer neutralizing antibodies against homologous and heterologous isolates than those elicited by monomeric YU2 gp120. Additionally, the GlaxoSmithKline family of adjuvants AS01B, AS02A, and AS03 induced higher levels of neutralizing antibodies compared to emulsification of the same immunogens in Ribi adjuvant. Further analysis of vaccine sera indicated that homologous virus neutralization was not mediated by antibodies to the V3 loop, although V3 loop-directed neutralization could be detected for some heterologous isolates. In most gp120-inoculated animals, the homologous YU2 neutralization activity was inhibited by a peptide derived from the YU2 V1 loop, whereas the neutralizing activity elicited by YU2 gp140 trimers was much less sensitive to V1 peptide inhibition. Consistent with a less V1-focused antibody response, sera from the gp140-immunized animals more efficiently neutralized heterologous HIV-1 isolates, as determined by two distinct neutralization formats. Thus, there appear to be qualitative differences in the neutralizing antibody response elicited by YU2 gp140 compared to YU2 monomeric gp120. Further mapping analysis of more conserved regions of gp120/gp41 may be required to determine the neutralizing specificity elicited by the trimeric immunogens.

* Corresponding author. Mailing address: Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Rm 4512, Bethesda, MD 20892. Phone: (301) 594-8690. Fax: (301) 480-0274. E-mail: richardwyatt{at}nih.gov.

{dagger} Supplemental material for this article may be found at http://jvi.asm.org/.

Journal of Virology, February 2006, p. 1414-1426, Vol. 80, No. 3
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.3.1414-1426.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dosenovic, P., Chakrabarti, B., Soldemo, M., Douagi, I., Forsell, M. N. E., Li, Y., Phogat, A., Paulie, S., Hoxie, J., Wyatt, R. T., Karlsson Hedestam, G. B. (2009). Selective Expansion of HIV-1 Envelope Glycoprotein-Specific B Cell Subsets Recognizing Distinct Structural Elements Following Immunization. J. Immunol. 183: 3373-3382 [Abstract] [Full Text]  
  • Morner, A., Douagi, I., Forsell, M. N. E., Sundling, C., Dosenovic, P., O'Dell, S., Dey, B., Kwong, P. D., Voss, G., Thorstensson, R., Mascola, J. R., Wyatt, R. T., Karlsson Hedestam, G. B. (2009). Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein. J. Virol. 83: 540-551 [Abstract] [Full Text]  
  • Li, Y., Svehla, K., Louder, M. K., Wycuff, D., Phogat, S., Tang, M., Migueles, S. A., Wu, X., Phogat, A., Shaw, G. M., Connors, M., Hoxie, J., Mascola, J. R., Wyatt, R. (2009). Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. J. Virol. 83: 1045-1059 [Abstract] [Full Text]  
  • Doria-Rose, N. A., Klein, R. M., Manion, M. M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C. W., Migueles, S. A., Wrammert, J., Ahmed, R., Nason, M., Wyatt, R. T., Mascola, J. R., Connors, M. (2009). Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies. J. Virol. 83: 188-199 [Abstract] [Full Text]  
  • Sundling, C., Schon, K., Morner, A., Forsell, M. N. E., Wyatt, R. T., Thorstensson, R., Hedestam, G. B. K., Lycke, N. Y. (2008). CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 89: 2954-2964 [Abstract] [Full Text]  
  • Binley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M., Wycuff, D., Harris, L., Hawkins, N., Wood, B., Nathe, C., Richman, D., Tomaras, G. D., Bibollet-Ruche, F., Robinson, J. E., Morris, L., Shaw, G. M., Montefiori, D. C., Mascola, J. R. (2008). Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. J. Virol. 82: 11651-11668 [Abstract] [Full Text]  
  • Laird, M. E., Igarashi, T., Martin, M. A., Desrosiers, R. C. (2008). Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response. J. Virol. 82: 11054-11065 [Abstract] [Full Text]  
  • Gustchina, E., Bewley, C. A, Clore, G. M. (2008). Sequestering of the Prehairpin Intermediate of gp41 by Peptide N36Mut(e,g) Potentiates the Human Immunodeficiency Virus Type 1 Neutralizing Activity of Monoclonal Antibodies Directed against the N-Terminal Helical Repeat of gp41. J. Virol. 82: 10032-10041 [Abstract] [Full Text]  
  • Vaine, M., Wang, S., Crooks, E. T., Jiang, P., Montefiori, D. C., Binley, J., Lu, S. (2008). Improved Induction of Antibodies against Key Neutralizing Epitopes by Human Immunodeficiency Virus Type 1 gp120 DNA Prime-Protein Boost Vaccination Compared to gp120 Protein-Only Vaccination. J. Virol. 82: 7369-7378 [Abstract] [Full Text]  
  • Kraft, Z., Strouss, K., Sutton, W. F., Cleveland, B., Tso, F. Y., Polacino, P., Overbaugh, J., Hu, S.-L., Stamatatos, L. (2008). Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses. J. Virol. 82: 5912-5921 [Abstract] [Full Text]  
  • Moore, P. L., Gray, E. S., Choge, I. A., Ranchobe, N., Mlisana, K., Abdool Karim, S. S., Williamson, C., Morris, L., and the CAPRISA 002 Study Team, (2008). The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. J. Virol. 82: 1860-1869 [Abstract] [Full Text]  
  • Ching, L. K., Vlachogiannis, G., Bosch, K. A., Stamatatos, L. (2008). The First Hypervariable Region of the gp120 Env Glycoprotein Defines the Neutralizing Susceptibility of Heterologous Human Immunodeficiency Virus Type 1 Isolates to Neutralizing Antibodies Elicited by the SF162gp140 Immunogen. J. Virol. 82: 949-956 [Abstract] [Full Text]  
  • Gustchina, E., Louis, J. M., Lam, S. N., Bewley, C. A., Clore, G. M. (2007). A Monoclonal Fab Derived from a Human Nonimmune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse Human Immunodeficiency Virus Type 1 Strains. J. Virol. 81: 12946-12953 [Abstract] [Full Text]  
  • Munk, C., Zielonka, J., Constabel, H., Kloke, B.-P., Rengstl, B., Battenberg, M., Bonci, F., Pistello, M., Lochelt, M., Cichutek, K. (2007). Multiple Restrictions of Human Immunodeficiency Virus Type 1 in Feline Cells. J. Virol. 81: 7048-7060 [Abstract] [Full Text]  
  • Dhillon, A. K., Donners, H., Pantophlet, R., Johnson, W. E., Decker, J. M., Shaw, G. M., Lee, F.-H., Richman, D. D., Doms, R. W., Vanham, G., Burton, D. R. (2007). Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. J. Virol. 81: 6548-6562 [Abstract] [Full Text]  
  • Zhang, P. F., Cham, F., Dong, M., Choudhary, A., Bouma, P., Zhang, Z., Shao, Y., Feng, Y.-R., Wang, L., Mathy, N., Voss, G., Broder, C. C., Quinnan, G. V. Jr (2007). Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. USA 104: 10193-10198 [Abstract] [Full Text]  
  • Dey, B., Pancera, M., Svehla, K., Shu, Y., Xiang, S.-H., Vainshtein, J., Li, Y., Sodroski, J., Kwong, P. D., Mascola, J. R., Wyatt, R. (2007). Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity. J. Virol. 81: 5579-5593 [Abstract] [Full Text]  
  • Law, M., Cardoso, R. M. F., Wilson, I. A., Burton, D. R. (2007). Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy. J. Virol. 81: 4272-4285 [Abstract] [Full Text]  
  • Brando, C., Ware, L. A., Freyberger, H., Kathcart, A., Barbosa, A., Cayphas, S., Demoitie, M.-A., Mettens, P., Heppner, D. G., Lanar, D. E. (2007). Murine Immune Responses to Liver-Stage Antigen 1 Protein FMP011, a Malaria Vaccine Candidate, Delivered with Adjuvant AS01B or AS02A. Infect. Immun. 75: 838-845 [Abstract] [Full Text]  
  • Kornbluth, R. S., Stone, G. W. (2006). Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J. Leukoc. Biol. 80: 1084-1102 [Abstract] [Full Text]  
  • Derby, N. R., Kraft, Z., Kan, E., Crooks, E. T., Barnett, S. W., Srivastava, I. K., Binley, J. M., Stamatatos, L. (2006). Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.. J. Virol. 80: 8745-8762 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»